ABSTRACT
Genomic platforms have proven to be more accurate as a prognostic tool than immunohistochemistry
studies in patients with early, hormone receptor positive, HER 2 negative breast cancer
and, in some cases, have also demonstrated predictive ability for chemotherapy benefit.
They are now widely applied in node-negative disease, but their use in node-positive
disease is more recent and more controversial, especially in premenopausal patients.
In this article, we review the use of these tests in node-positive disease.
Key words
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical Breast CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
REFERENCES
- Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials.Lancet Lond Engl. 2019; 393 (Apr 6): 1440-1452
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.Lancet Lond Engl. 2014; 384 (Jul 12): 164-172
- A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer.N Engl J Med. 2004; 351 (Dec 30): 2817-2826
- 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.N Engl J Med. 2021; 385 (Dec 16): 2336-2347
- Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study.J Clin Oncol Off J Am Soc Clin Oncol. 2010; 28 (Apr 10): 1829-1834
- Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.Lancet Oncol. 2010; 11 (Jan): 55-65
- Impact of Genomic Assay Testing and Clinical Factors on Chemotherapy Use After Implementation of Standardized Testing Criteria.The Oncologist. 2019; 24 (May): 595-602
- 21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology.Breast Cancer Res Treat. 2018; 168 (Feb): 69-77
- The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial).BMC Cancer. 2018; 18 (May 4): 526
- Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features.J Clin Oncol Off J Am Soc Clin Oncol. 2008; 26 (Sep 1): 4063-4071
- Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Score results in the SEER database.Breast Cancer Res Treat. 2017; 163 (Jun): 303-310
- Clinical outcomes in ER+ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: evidence from a large prospectively designed registry.NPJ Breast Cancer. 2017; 3: 32
- Breast cancer specific mortality (BCSM) in patients (pts) with node-negative (N0) and node-positive breast cancer (BC) guided by the 21-gene assay: A SEER-genomic population-based study.San Antonio Breast Cancer Symposium. 2018; ([P3-11-02])
- Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study.NPJ Breast Cancer. 2016; 2: 16017
- The Prognostic Significance of the Oncotype DX Recurrence Score in T1-2N1M0 Estrogen Receptor-Positive HER2-Negative Breast Cancer Based on the Prognostic Stage in the Updated AJCC 8th Edition.Ann Surg Oncol. 2019; 26 (May): 1227-1235
- Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.N Engl J Med. 2018; 379 (Jul 12): 111-121
- Supervised risk predictor of breast cancer based on intrinsic subtypes.J Clin Oncol Off J Am Soc Clin Oncol. 2009; 27 (Mar 10): 1160-1167
- Gene expression profiles from formalin fixed paraffin embedded breast cancer tissue are largely comparable to fresh frozen matched tissue.PloS One. 2011; 6 (Feb 11): e17163
- The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study.Breast Cancer Res Treat. 2009; 116 (Jul): 295-302
- 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.N Engl J Med. 2016; 375 (Aug 25): 717-729
- MINDACT: Longterm results of the large prospective trial testing the 70-gene signature MammaPrint as guidance for adjuvant chemotherapy in breast cancer patients.J Clin Oncol. 2020; 38: 506
- 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age.Lancet Oncol. 2021; 22 (Apr 1): 476-488
- Association of 70-Gene Signature Assay Findings With Physicians’ Treatment Guidance for Patients With Early Breast Cancer Classified as Intermediate Risk by the 21-Gene Assay.JAMA Oncol. 2018; 4 (Jan 11)e173470
- A diagnostic gene profile for molecular subtyping of breast cancer associated with treatment response.Breast Cancer Res Treat. 2012; 133: 37-47
- MammaPrint and BluePrint Molecular Diagnostics using targeted RNA Next-Generation Sequencing technology.J Mol Diagn JMD. 2019;
- Hallmarks of Cancer: The Next Generation.Cell. 2011; 144 (Mar 4): 646-674
- MammaPrint and BluePrint comprehensively capture the cancer hallmarks in early-stage breast cancer patients.Genes Chromosomes Cancer. 2022; ([Internet]637736544000000000 [citedJul 11]; Available from)
- Chemosensitivity predicted by BluePrint 80-gene functional subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST).Ann Surg Oncol. 2014; 21 (Oct): 3261-3267
- Genomic Testing in the Management of Early-Stage Breast Cancer.J Clin Outcomes Manag JCOM. 2017; 24 (May): 229-238
- Clinical utility of gene-expression signatures in early stage breast cancer.Nat Rev Clin Oncol. 2017; 14 (Oct): 595-610
- Clinical evidence supporting genomic tests in early breast cancer: Do all genomic tests provide the same information?.Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol. 2017; 43 (May): 909-920
- Multigene expression signatures in early hormone receptor positive HER 2 negative breast cancer.Radiol Oncol. 2019; 53 (Sep 24): 285-292
- Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype.Ann Oncol Off J Eur Soc Med Oncol. 2015; 26 (Aug): 1685-1691
- OPTIMA (Optimal Personalised Treatment of early breast cancer usIng Multi-parameter Analysis): A prospective trial to validate the predictive utility and cost-effectiveness of gene expression test-directed chemotherapy decisions.J Clin Oncol. 2016; 34 (May 20–TPS623): TPS623
- The PAM50 Risk-of-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast Cancer Clin Cancer.Res. 2022; 20: 1298-1305
- Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone.Ann Oncol Off J Eur Soc Med Oncol. 2014; 25 (Feb): 339-345
- PAM50 Risk of Recurrence Score Predicts 10-Year Distant Recurrence in a Comprehensive Danish Cohort of Postmenopausal Women Allocated to 5 Years of Endocrine Therapy for Hormone Receptor-Positive Early Breast Cancer.J Clin Oncol Off J Am Soc Clin Oncol. 2018; 36 (Mar 10): 735-740
- The Prosigna 50-gene profile and responsiveness to adjuvant anthracycline-based chemotherapy in high-risk breast cancer patients.NPJ Breast Cancer. 2020; 6 (Feb 26): 7
- Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.J Clin Oncol Off J Am Soc Clin Oncol. 2013; 31 (Aug 1): 2783-2790
- Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others.J Natl Cancer Inst. 2016; 108 (Sep)
- A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors.Clin Cancer Res Off J Am Assoc Cancer Res. 2011; 17 (Sep 15): 6012-6020
- Prediction of Distant Recurrence Using EndoPredict Among Women with ER+, HER2- Node-Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only.Clin Cancer Res Off J Am Assoc Cancer Res. 2019; 25 (Jul 1): 3865-3872
- Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor–Positive Breast Cancer.JAMA Oncol. 2018; 4 (Apr): 545-553
- Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trial.Breast Cancer Res BCR. 2014; 16 (Apr 12): R38
- Prognostic Value of EndoPredict in Women with Hormone Receptor–Positive, HER2-Negative Invasive Lobular Breast Cancer.Clin Cancer Res. 2020; 26 (Sep 1): 4682-4687
- Predicting Expected Absolute Chemotherapy Treatment Benefit in Women With Early-Stage Breast Cancer Using EndoPredict, an Integrated 12-Gene Clinicomolecular Assay.JCO Precis Oncol. 2019; (Dec): 1-10
- Genomic Signatures in Luminal Breast Cancer.Breast Care Basel Switz. 2020; 15 (Aug): 355-365
- Breast cancer index (BCI) predicts benefit of two-and-a-half versus five years of extended endocrine therapy in HR+ breast cancer patients treated in the ideal trial.J Clin Oncol. 2020; 38 (May 20–512): 512
- Comparative performance of Breast Cancer Index (BCIN+) and CTS5 in hormone receptor-positive (HR+) lymph node- positive (N+) breast cancer patients with one to three positive nodes (N1).J Clin Oncol. 2019; 37: 555https://doi.org/10.1200/JCO.2019.37.15_suppl.555
- from Extended Endocrine Therapy in Breast Cancer Patients Treated in the Adjuvant Tamoxifen–To Offer More?(aTTom).Trial. 2019; 30: 1176-1183https://doi.org/10.1093/annonc/mdz289
- Breast Cancer Index Predicts Extended Endocrine Benefit to Individualize Selection of Patients with HR+ Early-stage Breast Cancer for 10 Years of Endocrine Therapy.Clin Cancer Res Off J Am Assoc Cancer Res. 2021; 27 (Jan 1): 311-319
- Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis.J Natl Cancer Inst. 2006; 98 (Feb 15): 262-272
- Genomic Grade Index: An important tool for assessing breast cancer tumor grade and prognosis.Crit Rev Oncol Hematol. 2011; 77 (Jan 1): 20-29
- Comparison of the prognostic value of genomic grade index, Ki67 expression and mitotic activity index in early node-positive breast cancer patients.Ann Oncol Off J Eur Soc Med Oncol. 2013; 24 (Mar): 625-632
- Validation of the IHC4 Breast Cancer Prognostic Algorithm Using Multiple Approaches on the Multinational TEAM Clinical Trial.Arch Pathol Lab Med. 2016; 140 (Jan 1): 66-74
- Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.J Natl Cancer Inst. 2009; 101 (May 20): 736-750
- Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer.J Clin Oncol Off J Am Soc Clin Oncol. 2011; 29 (Nov 10): 4273-4278
- A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer.Clin Cancer Res Off J Am Assoc Cancer Res. 2010; 16 (Nov 1): 5222-5232
- Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update.J Clin Oncol. 2022; ([Internet]Apr 19 [cited 2022 Jul 3]; Available from)
- West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer.J Clin Oncol Off J Am Soc Clin Oncol. 2019; 37 (Apr 1): 799-808
- West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment.J Clin Oncol Off J Am Soc Clin Oncol. 2016; 34 (Jul 10): 2341-2349
- NCCN Guidelines Version 4.2022
Article Info
Publication History
Accepted:
July 24,
2022
Received in revised form:
July 12,
2022
Received:
March 23,
2022
Publication stage
In Press Journal Pre-ProofIdentification
Copyright
© 2022 Elsevier Inc. All rights reserved.
